Payment overview · 2025
General Payments
$621.45
49 reported records · 10 companies
Healthcare provider profile · identity verified
Aaron B Shives, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATERTOWN, SD · NPI 1659338747
Verified facts
What the public records show
CMS Open Payments records show Aaron B Shives, MD received $621.45 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.49 | 32.9% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.28 | 24.3% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.78 | 10.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.34 | 9.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.65 | 8.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.14 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.38 | 2.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.25 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.68 | 2.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $621.45 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $160.85 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.07 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $96.62 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.99 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $67.78 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $64.23 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.65 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.21 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 200 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 573 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 108 |
| Lisinopril | Lisinopril | 331 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 307 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 75 |
| Furosemide | Furosemide | 268 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 59 |
| Losartan Potassium | Losartan Potassium | 215 | 51 |
| Eliquis | Apixaban | 200 | 30 |
| Gabapentin | Gabapentin | 198 | 31 |
| Omeprazole | Omeprazole | 196 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 43 |
| Simvastatin | Simvastatin | 177 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 167 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 166 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 41 |
| Mounjaro | Tirzepatide | 155 | 21 |
| Warfarin Sodium | Warfarin Sodium | 155 | 27 |
| Allopurinol | Allopurinol | 150 | 31 |
| Trazodone Hcl | Trazodone Hcl | 147 | 34 |
| Metformin Hcl | Metformin Hcl | 144 | 31 |
| Memantine Hcl | Memantine Hcl | 139 | 19 |
| Metformin Hcl Er | Metformin Hcl | 137 | 32 |
| Carvedilol | Carvedilol | 130 | 32 |
| Donepezil Hcl | Donepezil Hcl | 130 | 25 |
| Potassium Chloride | Potassium Chloride | 130 | 28 |
| Sertraline Hcl | Sertraline Hcl | 125 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 115 | 31 |
| Fentanyl | Fentanyl | 111 | 15 |
| Famotidine | Famotidine | 109 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 29 |
| Bupropion Xl | Bupropion Hcl | 106 | 19 |
| Buspirone Hcl | Buspirone Hcl | 103 | 19 |
| Enalapril Maleate | Enalapril Maleate | 103 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 27 |
| Finasteride | Finasteride | 99 | 21 |
| Xarelto | Rivaroxaban | 96 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 17 |
| Tramadol Hcl | Tramadol Hcl | 94 | 28 |
| Alprazolam | Alprazolam | 92 | 27 |
| Farxiga | Dapagliflozin Propanediol | 89 | 22 |
| Montelukast Sodium | Montelukast Sodium | 87 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 25 |
| Mirtazapine | Mirtazapine | 79 | 13 |
| Trulicity | Dulaglutide | 72 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Jantoven | Warfarin Sodium | 50 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 40 |
| Latanoprost | Latanoprost | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 11 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 16 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Digoxin | Digoxin | 33 | 11 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 17 |
| Prednisone | Prednisone | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 16 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 26 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Gattex | Teduglutide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Etodolac Er | Etodolac | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $621.45 · 49 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, INJECTAFER, Jornay PM, Kerendia, MOUNJARO, NURTEC ODT, PREVNAR 20, QULIPTA, ROTATEQ, UBRELVY, VAXNEUVANCE, VRAYLAR, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error